Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CEScientific InterchangesState of the Science SummitNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Watch
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

Kilian Salerno, MD

Advertisement

Articles by Kilian Salerno, MD

Dr. Salerno Discusses Hypofractionation for Early Breast Cancer

ByKilian Salerno, MD
April 1st 2016

Kilian Salerno, MD, director of Breast Radiation and Soft Tissue/Melanoma Radiation, Roswell Park Cancer Institute, discusses hypofractionated radiotherapy for the treatment of patients with early-stage breast cancer.

Advertisement

Latest Updated Articles

  • Dr. Salerno Discusses Hypofractionation for Early Breast Cancer
    Dr. Salerno Discusses Hypofractionation for Early Breast Cancer

    April 1st 2016



Advertisement
Advertisement

Trending on OncLive

1

FDA Grants Breakthrough Therapy Designation to JBS-003 for Radiation De-Escalation in HPV+ Oropharyngeal Cancer

2

Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC

3

Etentamig Meets PFS, ORR Primary End Points in Triple-Class Exposed R/R Myeloma

4

A New Player in the Adjuvant Setting? GLP-1 Agonists and the Fight Against Breast Cancer Metastasis

5

Novel Therapies Are Poised to Answer Questions and Reinvigorate Hematologic Oncology at SOHO 2026

  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo
Download on Apple
Download on Google Play

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us